Passive Immunoprophylaxis for the Protection of the Mother and Her Baby: Insights from In Vivo Models of Antibody Transport by Yanqun Xu, Iftekhar Mahmood, Lilin Zhong, Pei Zhang, Evi B. Struble

“…The use of appropriate animal models of placental transfer and infectious disease during pregnancy would facilitate pharmacokinetic modeling to derive a starting dose in clinical trials.…”
Get full text

Correlation of Macular Focal Electroretinogram with Ellipsoid Zone Extension in Stargardt Disease by Edoardo Abed, Giorgio Placidi, Luigi Calandriello, Marco Piccardi, Francesca Campagna, Matteo Bertelli, Angelo Maria Minnella, Maria Cristina Savastano, Benedetto Falsini

“…A precise assessment of macular cone function by FERG recording may be useful to monitor the progression of STGD1 and to select the optimal candidates to include in future clinical trials to treat this disease.…”
Get full text

Contribution of Statins towards Periodontal Treatment: A Review by Catherine Petit, Fareeha Batool, Isaac Maximiliano Bugueno, Pascale Schwinté, Nadia Benkirane-Jessel, Olivier Huck

“…Herein, the adjunctive use of statins in periodontal therapy in vitro, in vivo, and in clinical trials was reviewed. Statins act through several pathways to modulate inflammation, immune response, bone metabolism, and bacterial clearance. …”
Get full text

Managing pediatric psoriasis: update on treatments and challenges—a review by A. A. Hebert, J. Browning, P. C. Kwong, A. M. Duarte, H. N. Price, E. Siegfried

“…A growing number of clinical trials using biologic agents for pediatric psoriasis aim to broaden available treatment options but may also raise unique concerns associated with the use of these medications in children.Conclusion Pediatric psoriasis is underrecognized and often undertreated. …”
Get full text

Busting the Breast Cancer with AstraZeneca’s Gefitinib by S. Chemmalar, A. R. Intan Shameha, Che Azurahanim Che Abdullah, Nor Asma Ab Razak, Loqman Mohamad Yusof, Mokrish Ajat, Kim Wei Chan, Md Zuki Abu Bakar Zakaria

“…Unfortunately, in clinical trials, GEF did not show the outcomes expected with complete response and disease progress. …”
Get full text

Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy by Shixue Chen, Lingling Li, Fan Zhang, Yu Wang, Yi Hu, Lei Zhao

“…There are 23 platforms available to generate 62 BsAbs which can be further divided into IgG-like ones and fragment-based ones, and more than 50 molecules are undergoing clinical trials currently. BsAbs with IgG-like architecture exhibit superior advantages in structure (similar to natural antibodies), pharmacokinetics, half-life, FcR-mediated function, and biological activity. …”
Get full text

Opportunities for implementing digital applications to monitor the impact of risk-minimization measures within the pharmacovigilance process: Scoping review of published literature by Ilko Getov, Denitsa Panayotova, Stanimir Dobrev, Maria Dimitrova, Valentina Petkova

“…This is crucial for identifying risks not observed during clinical trials. Digital tools offer potential benefits by providing real-time reporting, comprehensive safety data, and increased patient engagement, thus addressing the challenges of underreporting and incomplete data in pharmacovigilance. …”
Get full text

Targeting heparan sulfate proteoglycans as an effective strategy for inhibiting cancer cell migration and invasiveness compared to heparin by Lorenzo Depau, Jlenia Brunetti, Chiara Falciani, Elisabetta Mandarini, Marta Zanchi, Maria Francesca Paolocci, Marta Garfì, Alessandro Pini, Luisa Bracci

“…Despite a strong conceptual basis and promising preclinical results, clinical trials have failed to demonstrate any significant advantage of administering heparin to oncology patients. …”
Get full text

Mechanisms Underlying the Osteo- and Adipo-Differentiation of Human Mesenchymal Stem Cells by Yu Zhang, Dilaware Khan, Julia Delling, Edda Tobiasch

“…In this review, the current findings for adipo- and osteo-differentiation are summarized together with a brief statement on first clinical trials.…”
Get full text

Emerging Pharmacological Interventions for Chronic Venous Insufficiency: A Comprehensive Systematic Review and Meta-Analysis of Efficacy, Safety, and Therapeutic Advances by Camila Botelho Miguel, Ranielly de Souza Andrade, Laise Mazurek, Melissa Carvalho Martins-de-Abreu, Jamil Miguel-Neto, Aurélio de Melo Barbosa, Glicélia Pereira Silva, Aristóteles Góes-Neto, Siomar de Castro Soares, Javier Emilio Lazo-Chica, Wellington Francisco Rodrigues

“…However, limitations such as high heterogeneity, small sample sizes, and methodological inconsistencies highlight the need for more robust and standardized clinical trials. This study underscores the importance of personalized and cost-effective strategies, particularly in resource-limited settings.…”
Get full text

Cytokine Profile of Patients with Allergic Rhinitis Caused by Pollen, Mite, and Microbial Allergen Sensitization by Yury A. Tyurin, Svetlana A. Lissovskaya, Rustem S. Fassahov, Ilshat G. Mustafin, Anton F. Shamsutdinov, Marina A. Shilova, Albert A. Rizvanov

“…Thus, along with other clinical trials, the study performed would clarify some aspects of molecular pathogenesis of human allergic rhinitis.…”
Get full text

Pancreatic Cancer: Current Concepts, Trends, and Future Directions by Patrick Wenzel, Carolin Mogler, Kıvanç Görgülü, Hana Algül

“…Over the last 2 decades, clinical trials have significantly improved disease prognosis and patient survival. …”
Get full text

Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies by Venkata Lokesh Battula, Abhishek Maiti, Adishwar Rao, Akriti Agrawal, Gautam Borthakur

“…Insights from murine models and clinical data in humans show improved overall survival, leukemia-free survival, reduced risk of relapse, enhanced graft-versus-leukemia effect, and decreased graft-versus-host disease in patients with AML who have higher reconstitution of γδ T cells following allogeneic hematopoietic stem cell transplantation. Clinical trials leveraging γδ T cell biology have used unmodified and modified allogeneic cells as well as bispecific engagers and monoclonal antibodies. …”
Get full text

A Revision on the Effectiveness of Omega-3 Polyunsaturated Fatty Acids as Monotherapy in the Treatment of Major Depressive Disorder by Tommaso Accinni, Matteo Panfili, Lorenzo Tarsitani, Massimo Biondi, Massimo Pasquini, Annalisa Maraone

“…Two well-trained reviewers independently looked at the most significant randomized clinical trials (RCTs) from the PubMed database regarding PUFAs’ employment in MDD compared to placebo; “major depressive disorder” and “omega-3 fatty acids,” or “omega-6 fatty acids,” or “polyunsaturated fatty acids (PUFA),” or “n − 3 polyunsaturated fatty acids,” or “eicosapentaenoic acid (EPA),” or “docosahexaenoic acid (DHA)” were used as the medical subject keywords. …”
Get full text

Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life by Andrew Blauvelt, Mark Boguniewicz, Patrick M. Brunner, Paula C. Luna, Pinaki Biswas, Marco DiBonaventura, Saleem A. Farooqui, Ricardo Rojo, Michael C. Cameron

“…Outcomes measuring skin clearance, itch, and quality of life were evaluated.Results Both nonresponders (n = 548) and responders (n = 260) treated with abrocitinib had rapid and clinically meaningful improvement in skin clearance, itch, and quality of life compared with placebo.Conclusion Patients with moderate-to-severe atopic dermatitis treated with abrocitinib who did not achieve an Investigator’s Global Assessment 0/1 response at week 12 still experienced rapid, clinically meaningful improvements across several other validated measures of efficacy and quality of life.ClinicalTrials.gov NCT02780167, NCT03349060, NCT03575871…”
Get full text

Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option? by Daniele Fanale, Giuseppe Bronte, Francesco Passiglia, Valentina Calò, Marta Castiglia, Florinda Di Piazza, Nadia Barraco, Antonina Cangemi, Maria Teresa Catarella, Lavinia Insalaco, Angela Listì, Rossella Maragliano, Daniela Massihnia, Alessandro Perez, Francesca Toia, Giuseppe Cicero, Viviana Bazan

“…Cryptophycins, combretastatins, ombrabulin, soblidotin, D-24851, epothilones and discodermolide were used in clinical trials. Some of them showed antiangiogenic and antivascular activity and others showed the ability to overcome multidrug resistance, supporting their possible use in chemotherapy.…”
Get full text

Dehydrothyrsiferol Against Cutaneous Leishmaniasis: Treatment Outcome in a Murine Model by Atteneri López-Arencibia, Carlos J. Bethencourt-Estrella, Desirée San Nicolás-Hernández, Rubén L. Rodríguez-Expósito, Angélica Domínguez-de-Barros, Lizbeth Salazar-Villatoro, Maritza Omaña-Molina, Francisco Cen-Pacheco, Ana R. Díaz-Marrero, José J. Fernández, Elizabeth Córdoba-Lanús, Jacob Lorenzo-Morales, José E. Piñero

“…One of the most important steps in preclinical drug discovery is to demonstrate the in vivo efficacy of potential leishmanicidal compounds and good characteristics at the level of parasite killing prior to initiating human clinical trials. This paper describes the use of dehydrothyrsiferol (DT), isolated from the red alga <i>Laurencia viridis</i>, in a pharmaceutical form supported on Sepigel, and the in vivo efficacy against a mouse model of cutaneous leishmaniasis. …”
Get full text

Metformin Ameliorates D-Galactose-Induced Senescent Human Bone Marrow-Derived Mesenchymal Stem Cells by Enhancing Autophagy by Pingting Ye, Lei Feng, Dan Zhang, Ruihao Li, Yixuan Wen, Xiaohan Tong, Shuo Shi, Chunyan Dong

“…Human bone marrow-derived mesenchymal stem cells (hBMSCs) are promising candidates for stem cell therapy in clinical trials. Applications of hBMSCs in clinical therapy are limited by cellular senescence due to long-term ex vivo expansion. …”
Get full text

Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy by Sarah Nikiforow, John Haanen, Omid Hamid, Igor Puzanov, Rodabe Amaria, Amod Sarnaik, Marcus O Butler, Michael R Bishop, Allison Betof Warner, Adam J Schoenfeld, Krishna Komanduri

“…Adoptive cell therapy with autologous, ex vivo-expanded, tumor-infiltrating lymphocytes (TILs) is being investigated for treatment of solid tumors and has shown robust responses in clinical trials. Based on the encouraging efficacy, tolerable safety profile, and advancements in a central manufacturing process, lifileucel is now the first US Food and Drug Administration (FDA)-approved TIL cell therapy product. …”
Get full text

Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study) by Isabel Machuca, Arantxa Dominguez, Rosario Amaya, Cristina Arjona, Irene Gracia-Ahufinger, Maravillas Carralon, Rosa Giron, Isabel Gea, Natividad De Benito, Andres Martin, Fatima Galan, Jose Antonio Martinez, Rayden Iglesias, Jaume Revuelto, Juan Jose Caston, Angela Cano, Elisa Ruiz-Arabi, Luis Martínez-Martínez, Julian Torre-Cisneros

“…Conclusions Imipenem/cilastatin/relebactam may represent a treatment option for patients with DTR-P. aeruginosa infections, which should be validated in prospective clinical trials.…”
Get full text